Cargando…

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating at...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhenxian, Zhu, Haimei, Liu, Hao, Liu, Dayue, Liu, Jianhe, Jiang, Jiazheng, Zhang, Yi, Qin, Zhang, Xu, Yijia, Peng, Yuan, Liu, Bin, Long, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199622/
https://www.ncbi.nlm.nih.gov/pubmed/37208681
http://dx.doi.org/10.1186/s12951-023-01904-4
_version_ 1785044971172134912
author Li, Zhenxian
Zhu, Haimei
Liu, Hao
Liu, Dayue
Liu, Jianhe
Jiang, Jiazheng
Zhang, Yi
Qin, Zhang
Xu, Yijia
Peng, Yuan
Liu, Bin
Long, Yun
author_facet Li, Zhenxian
Zhu, Haimei
Liu, Hao
Liu, Dayue
Liu, Jianhe
Jiang, Jiazheng
Zhang, Yi
Qin, Zhang
Xu, Yijia
Peng, Yuan
Liu, Bin
Long, Yun
author_sort Li, Zhenxian
collection PubMed
description PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating atherosclerosis. In this study, by utilizing the significant advantages of nano-materials, a biomimetic nanoliposome loading with Evolocumab (Evol), a PCSK9 inhibitor, was designed to alleviate atherosclerosis. In vitro results showed that (Lipo + M)@E NPs up-regulated the levels of α-SMA and Vimentin, while inhibiting the expression of OPN, which finally result in the inhibition of the phenotypic transition, excessive proliferation, and migration of VSMCs. In addition, the long circulation, excellent targeting, and accumulation performance of (Lipo + M)@E NPs significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE(−/−) mice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01904-4.
format Online
Article
Text
id pubmed-10199622
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101996222023-05-21 Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy Li, Zhenxian Zhu, Haimei Liu, Hao Liu, Dayue Liu, Jianhe Jiang, Jiazheng Zhang, Yi Qin, Zhang Xu, Yijia Peng, Yuan Liu, Bin Long, Yun J Nanobiotechnology Research PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating atherosclerosis. In this study, by utilizing the significant advantages of nano-materials, a biomimetic nanoliposome loading with Evolocumab (Evol), a PCSK9 inhibitor, was designed to alleviate atherosclerosis. In vitro results showed that (Lipo + M)@E NPs up-regulated the levels of α-SMA and Vimentin, while inhibiting the expression of OPN, which finally result in the inhibition of the phenotypic transition, excessive proliferation, and migration of VSMCs. In addition, the long circulation, excellent targeting, and accumulation performance of (Lipo + M)@E NPs significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE(−/−) mice. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01904-4. BioMed Central 2023-05-19 /pmc/articles/PMC10199622/ /pubmed/37208681 http://dx.doi.org/10.1186/s12951-023-01904-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Zhenxian
Zhu, Haimei
Liu, Hao
Liu, Dayue
Liu, Jianhe
Jiang, Jiazheng
Zhang, Yi
Qin, Zhang
Xu, Yijia
Peng, Yuan
Liu, Bin
Long, Yun
Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title_full Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title_fullStr Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title_full_unstemmed Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title_short Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
title_sort evolocumab loaded bio-liposomes for efficient atherosclerosis therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199622/
https://www.ncbi.nlm.nih.gov/pubmed/37208681
http://dx.doi.org/10.1186/s12951-023-01904-4
work_keys_str_mv AT lizhenxian evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT zhuhaimei evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT liuhao evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT liudayue evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT liujianhe evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT jiangjiazheng evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT zhangyi evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT qinzhang evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT xuyijia evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT pengyuan evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT liubin evolocumabloadedbioliposomesforefficientatherosclerosistherapy
AT longyun evolocumabloadedbioliposomesforefficientatherosclerosistherapy